Common stock, par value $0.001 per share
- Symbol
- REVB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Revelation Biosciences, Inc.
REVBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1.…
Press release in this filing
Revelation Biosciences, Inc. Announces Financial Results →Company context
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention for acute kidney injury (“AKI”), GEM-CKD as a treatment for chronic kidney disease (“CKD”), GEM-PSI as a prevention for post surgical infection (“PSI”), and GEM-PBI as a prevention of infection in severe burn patients requiring hospitalization (“PBI”). The Company was incorporated in the state of Delaware on November 20, 2019 (originally as Petra Acquisition, Inc.) and is based in San Diego, California.
Current securities
Registered securities in this filing
REVELATION BIOSCIENCES, INC. · 8-K · Filed 2026-08-06
Redeemable warrants, each exercisable for a 1/201,600th share of common stock at an exercise price of $2,318,400 per share
- Symbol
- REVBW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Series B junior participating preferred purchase rights
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- RIGHT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1.
The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Filed exhibits (1)
EX-99.1 2 revb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO - August 6, 2026 - Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026. Corporate Highlights • Announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board • Continued progress on Phase 2/3 clinical study start up activities • Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini “Start-up activities for our pivotal clinical study of Gemini in acute kidney injury patients continue to progress,” said James Rolke, Chief Executive Officer of Revelation. “Our focus remains on starting enrollment by year-end, for the benefit of those patients and, ultimately, to deliver value for our shareholders.” Results of Operations As of…
Open exhibit ↗